الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 32 |  |  |
| | | from | 32 | | |
Abstract
This study included 135 consecutive patients, [60 males (59.3%), 55 females (40.7%), with a mean age ± SD of 62.5±11.7 years, ranging from 22 to 96 years] with a diagnosis of NSTEMI at CCU of Minia University Hospital and CCU of Minia Insurance Hospital in the period from June 2013 to June 2014. The serum resistin levels were measured from blood taken immediately at admission. Follow up of our patients was for 6±3 months post NSTEMI at Cardiology outpatient clinic of Minia University Hospital and by telephone contacts for investigating endpoints.
Patients were classified according to mean serum resistin level (10.8 ng/ml) into 2 groups, group 1 with high resistin level and group 2 with low resistin level. Two predefined endpoints were detected for MACE. Endpoint 1 included cardiovascular mortality, urgent revascularization and reinfarction. Endpoint 2 included rehospitalization for other cardiac causes.
There was no statistically significant difference between both groups in any of the clinical parameters or demographic data and also there was no statistically significant difference between their clinical presentation at CCU or laboratory data. However, when it comes to endpoints, there was highly statistically significant difference between the 2 groups groups with p value (<0.001). There was 48 patients of group 1 with high resistin level (18.3±2.2) and all reached to endpoints. On the contrary was no MACE at group 2 with low resistin level (6.7±1.8).